Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

[Experience of using genfaxon for treating patients with relapsing-remitting multiple sclerosis in the Russian Federation.]
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.
Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects.
New York Academy of Sciences: T Cells at the Interface of Immune-CNS Cross-Talk
Control of oxidative stress and inflammation in sickle cell disease with the Nrf2 activator dimethyl fumarate.
Ustekinumab success in refractory Crohn’s disease
Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system.
Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
American Academy of Neurology Annual Meeting
Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study.
[The membrane stabilizing effect of glatiramer acetate in multiple sclerosis].
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Individual axons regulate the myelinating potential of single oligodendrocytes in vivo.
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.
Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
Chronic cladribine administration increases amyloid Beta Peptide generation and plaque burden in mice.
LKB1-regulated adaptive mechanisms are essential for neuronal survival following mitochondrial dysfunction.
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple scl
Gordon Research Conference on Immunochemistry & Immunobiology
Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies: A Comparative Study.
Clinically feasible MTR is sensitive to cortical demyelination in MS.
Acorda Therapeutics announces initiation of AMPYRA® proof-of-concept study in patients with post-stroke deficits
Brain Volume Loss during the First Year of Interferon-Beta Treatment: Baseline Inflammation and Tissue-Specific Volume Dynamics.
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
Synthetic Biologics Announces Issuance of U.S. Patent Adding Another Layer of Protection for the Use of Oral Estriol Candidate, Trimesta™, for Multiple Sclerosis

Pages